Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 8/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.47 |
| ▸ | RET | P07949 | 3/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 2/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 2/20 | 0.47 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.47 |
| ▸ | TEC | P42680 | 1/20 | 0.47 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.47 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401723 | 0.90 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CGKDR | |
| SCHEMBL1401676 | 0.90 | KDR (0.48) | PIK3CDPIK3CAPIK3CBPIK3CGKDR | |
| SCHEMBL1401670 | 0.87 | EGFR (0.56) | KDREGFRERBB2RETRIPK2 | |
| SCHEMBL1401658 | 0.85 | KDR (0.48) | KDREGFRERBB2RETRIPK2 | |
| SCHEMBL1401703 | 0.85 | KDR (0.58) | KDREGFRERBB2RETRIPK2 | |
| SCHEMBL1401639 | 0.84 | KDR (0.63) | KDREGFRERBB2RETRIPK2 | |
| SCHEMBL1401656 | 0.84 | KDR (0.63) | KDREGFRERBB2RETRIPK2 | |
| SCHEMBL1401725 | 0.80 | PIK3CD (0.48) | PIK3CDPIK3CAPIK3CBPIK3CGKDR | |
| SCHEMBL12369330 | 0.80 | EGFR (0.57) | PIK3CDPIK3CAPIK3CBPIK3CGKDR | |
| SCHEMBL28421305 | 0.80 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CGKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | claimed |
| EP-2292615-A1 | Quinazoline compounds | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | claimed |
| US-20080027069-A1 | Quinazoline compounds | ASTRAZENECA AB | 2008-01-31 | — | — | US | claimed |
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | ASTRAZENECA AB (SE) | 2005-04-21 | — | — | US | claimed |
| EP-1474420-A1 | QUINAZOLINE COMPOUNDS | Astrazeneca AB (SE) | 2004-11-10 | — | — | EP | claimed |
| WO-2003064413-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | WO | claimed |
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | disclosed |
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | disclosed |
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | disclosed |
| EP-2292615-A1 | Quinazoline compounds | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| EP-2292615-A1 | Quinazoline compounds | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| US-20100029673-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| US-20090156821-A1 | Quinazoline compounds | ASTRAZENECA AB | 2009-06-18 | — | — | US | disclosed |
| US-20080027069-A1 | Quinazoline compounds | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| US-7268230-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-09-11 | — | — | US | disclosed |
| US-7268230-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-09-11 | — | — | US | disclosed |
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | disclosed |
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | ASTRAZENECA AB (SE) | 2005-04-21 | — | — | US | disclosed |
| EP-1474420-A1 | QUINAZOLINE COMPOUNDS | Astrazeneca AB (SE) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003064413-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | SRC, TEK, FLT4 | PIK3CD 791/4885PIK3CA 1004/4885PIK3CB 735/4885 |
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | VEGFA, FLT4, FLT1 | PIK3CD 1529/4885PIK3CA 1278/4885PIK3CB 2112/4885 |
| US-20100029673-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | SRC, CHUK, CTTN | PIK3CD 426/4885PIK3CA 402/4885PIK3CB 468/4885 |
| US-20090156821-A1 | Quinazoline compounds | VEGFA, FLT4, FLT1 | PIK3CD 1331/4885PIK3CA 1090/4885PIK3CB 1895/4885 |
| US-20080027069-A1 | Quinazoline compounds | VEGFA, FLT4, FLT1 | PIK3CD 1331/4885PIK3CA 1090/4885PIK3CB 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.